About Triquetra Medicines

About Triquetra Medicines

Triquetra Medicines is a Swedish pharmaceutical company dedicated to creating a third source of prescription medicines alongside conventional branded products and generics.

We identify and develop therapeutic opportunities that fall between traditional pharmaceutical business models. These opportunities often possess strong scientific and clinical foundations but remain underserved because they do not fit the commercial priorities of either innovative pharmaceutical companies or generic manufacturers.

Why a Third Source of Medicines?

Modern healthcare depends heavily on two established sources of prescription medicines: innovative branded products and generics. Both play essential roles, but neither model captures every valuable therapeutic opportunity.

As healthcare systems face growing pressure from aging populations, rising costs, and increasing demand for effective treatments, new approaches to pharmaceutical development are needed.

Our Approach

We focus on opportunities emerging from academic research and pharmaceutical R&D that already possess substantial therapeutic validation. By combining focused development strategies with innovative product-specific commercial models, we can advance medicines that conventional pharmaceutical companies often cannot -or choose not to- develop.

This allows us to reduce development complexity, shorten timelines, lower risk, and ultimately improve affordability without compromising quality, efficacy, or safety.

Our Philosophy

Patients and physicians should not be forced to choose between innovation, quality, availability, and affordability. We believe these objectives can and should coexist.

At Triquetra Medicines, commercial sustainability remains essential. However, we view it as a means of expanding patient access to meaningful therapies rather than an objective in itself.

Our goal is straightforward: to provide innovative prescription medicines that meet modern standards of efficacy, safety, and quality while remaining broadly accessible to patients and healthcare systems across Europe and beyond